Dr Nagender Sharma

Dr. Nagender Sharma is an accomplished medical oncologist with more than 8 years of experience in advanced cancer care. He specializes in solid tumor management, including thoracic, gastrointestinal, and breast malignancies. Having trained at premier institutions such as the Cancer Institute (WIA), Chennai, and Medanta The Medicity, Dr. Sharma integrates precision oncology with evidence-based treatment. His involvement in global clinical trials and research reflects his dedication to advancing cancer therapeutics and personalized care.

Educational Qualification:

• DM (Medical Oncology) – Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu
• DNB (Medical Oncology) – National Board of Examinations, New Delhi
• MD (Medicine) – M.R. Medical College, Gulbarga, Karnataka
• MBBS – Kasturba Medical College, Mangalore, Karnataka
• ESMO Certification – European Society of Medical Oncology (Europe)

Professional Experience:

• Associate Director – Medical Oncology, Max Healthcare (Present)
• Consultant – Medical Oncology & Hematology, Medanta The Medicity, Gurugram (Feb 2020 – Aug 2022)
• Associate Consultant – Medical Oncology & Hematology, Medanta The Medicity, Gurugram (2017 – 2020)
• Senior Resident – Medical Oncology & Hematology, Medanta The Medicity, Gurugram (2012 – 2013)
• Ex-Assistant Professor – Internal Medicine, MAMC, Agroha, Hisar

Awards and Achievements:

• Active participation in global oncology research and clinical trials
• Recognized for contributions in real-world cancer treatment outcome studies

Professional Membership:

• Indian Society of Medical & Paediatric Oncology (ISMPO)
• Indian Cooperative Oncology Network (ICON)
• European Society of Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)

Research Papers & Publications:

• Co-Principal Investigator in TALAPRO-III Phase-III International Multicenter Study
• TALAPRO-3, A Phase III Randomised, Double Blind, Study of Talazoparib with Enzalutamide Versus Placebo with Enzalutamide in Men with DDR Gene Mutated Metastatic Castration Sensitive Prostate Cancer
• Paralysis of Diaphragm after SBRT of Lung Cancer (J Radiosurgery)
• Subclinical Hyperthyroidism in post Immunotherapy Lung Cancer on FFDG PET/CT-An Incidental Observation (IJC)
• Ecacy and Safety of Palbociclib in Treatment of HR-positive Advanced Breast Cancer Patients: A Single Center Real-world Experience (JCO)
• Survival Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin: A Real-world Evidence Study from India (JCO)